Leukemia CLL (Chronic Lymphocytic Leukemia)
Chronic lymphocytic leukemia explained: prognosis markers like IGHV and TP53, watch-and-wait and BTK inhibitors. 1-hour video consult with a specialist.
Chronic lymphocytic leukemia, often called leukemia CLL, is the most common leukemia in adults in the United States, and it often grows slowly. Many people live with CLL for years, some without ever needing treatment. Your outlook depends on markers such as IGHV status and TP53, and today's treatments work far better than those of a decade ago. Here is what a CLL diagnosis means and how a specialist can help.
Medically reviewed by Dr. Muhammad Raza Naqvi, MD, USA board-certified hematologist-oncologist.
What is leukemia CLL?
In CLL, the bone marrow makes too many abnormal B lymphocytes, a type of white blood cell. They build up in the blood, bone marrow and lymph nodes. CLL is often found by chance on a routine blood test showing a high lymphocyte count. When the disease is mainly in the lymph nodes, it is called small lymphocytic lymphoma (SLL) and is treated the same way.
Symptoms
Many people have no symptoms at first. Over time CLL can cause swollen lymph nodes, tiredness, frequent infections, night sweats, fever, weight loss or a feeling of fullness from an enlarged spleen.
Leukemia CLL prognosis
CLL prognosis is often good: nearly 9 in 10 people are alive 5 years after diagnosis, and many live much longer. Your doctor looks at:
Stage (Rai or Binet): how much CLL affects the lymph nodes, spleen and blood counts.
IGHV mutation status: mutated IGHV usually means slower disease and a better outlook.
TP53 mutation or del(17p): linked to more aggressive disease; changes the best treatment.
Other FISH results (del(13q), trisomy 12, del(11q)): help predict how the disease will behave.
Beta-2 microglobulin: a blood marker linked to disease burden.
These are combined in scores such as CLL-IPI. Ask for your IGHV and TP53 results before starting treatment.
Watch and wait: what it means
If you feel well and your blood counts are stable, the standard approach is active monitoring, often called watch and wait. Starting treatment early does not help people live longer at this stage. Treatment starts if blood counts fall, lymph nodes or the spleen grow quickly, the lymphocyte count rises fast, or symptoms appear.
Treatment options
BTK inhibitors: daily pills such as acalabrutinib, zanubrutinib and ibrutinib, usually taken long-term.
Venetoclax-based treatment: venetoclax with obinutuzumab, given for a fixed time (about 1 year).
Newer options for relapsed CLL: including non-covalent BTK inhibitors such as pirtobrutinib, and CAR-T cell therapy.
Clinical trials.
The right choice depends on your markers, other health conditions, other medicines and whether you prefer fixed-duration or continuous treatment.
How CLL coaching works
Book online (a New Diagnosis session or a Treatment Side Effect Discussion) and complete a short intake form.
Upload your pathology, scan reports and lab results.
Dr. Naqvi reviews your records before the visit.
Meet by secure video for a full hour and leave with clear next steps and a written summary for your care team.
Frequently asked questions
Is CLL curable?
Most treatments control CLL rather than cure it, often for many years. Many people with CLL live a normal or near-normal lifespan.
Why am I not being treated right away?
For early CLL without symptoms, careful monitoring is the standard of care, because early treatment does not extend life.
Does CLL raise infection risk?
Yes. Ask about vaccines (avoid live vaccines) and when to call your doctor about a fever.
